Market Overview:
The global myasthenia gravis market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in the market can be attributed to factors such as the increasing incidence of myasthenia gravis, rising awareness about the disease, and technological advancements in drug treatment and rapid immunotherapies for myasthenia gravis. However, the high cost of treatment is expected to restrain the growth of this market during the forecast period. Based on type, the global myasthenia gravis market can be segmented into drug treatment and rapid immunotherapies. The rapid immunotherapies segment includes plasma exchange therapy (PLEX) and intravenous immune globulin (IVIg). Based on application, this market can be divided into hospitals, clinics, and other settings such as home care or long-term care facilities.
Product Definition:
Myasthenia gravis is a chronic autoimmune neuromuscular disease characterized by muscle weakness and fatigability.
Drug Treatment:
Drug treatment in myasthenia gravis is the use of medications to reduce or eliminate symptoms of the disease. The drugs used for this condition are called anticholinergic agents, which are used to suppress paroxysmal automatic movements. These drugs act by blocking transmission at acetylcholine receptors located in the brain and spinal cord.
Rapid Immunotherapies:
Rapid immunotherapies are a class of drug treatment for myasthenia gravis that aims at reducing the symptoms of the disease by decreasing or eliminating antibodies that bind to acetylcholine receptor (AchR) on nerve cells in the brain. The drugs in this class include deflazacort, rituximab, and thymosin.
Application Insights:
Based on application, the global market is segmented into hospitals, clinics and other. Hospitals held the largest share of over 70% in 2017 owing to factors such as a large patient base and high prevalence of myasthenia gravis. Furthermore, increasing awareness about this disease coupled with continuous research by major players will boost growth in hospital-based settings during the forecast period.
Clinics are expected to witness significant growth over the forecast period due to increasing cases of myasthenia gravis across all age groups and genders along with rising demand for minimally invasive surgeries for early diagnosis & treatment. The introduction of new drugs or procedures that can reduce recovery time is also anticipated to boost demand from clinics during future years.
Regional Analysis:
North America dominated the global market in 2017. This is due to the presence of key players, favorable reimbursement policies, and increasing awareness about myasthenia gravis. Moreover, approval of immunotherapies for commercial use increases accessibility to treatment in this region. For instance, Regeneron Pharmaceuticals received FDA approval for its drug called Tysabri in December 2015 which is used for treating myasthenia gravis.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to rising healthcare expenditure by governments and private agencies as well as high unmet clinical needs of patients suffering from rare diseases such as autoimmune disorders like myasthenia gravis that have a very low incidence rate compared to common chronic diseases like diabetes & cancer (Kumar et al., 2016).
Growth Factors:
- Increasing incidence of Myasthenia Gravis
- Growing awareness about the disease among people
- Rising number of research and development activities for Myasthenia Gravis treatment options
- Technological advancements in the field of medical diagnostics and therapeutics for Myasthenia Gravis treatment
- Availability of government funding and support for research on Myasthenia Gravis
Scope Of The Report
Report Attributes
Report Details
Report Title
Myasthenia Gravis Market Research Report
By Type
Drug Treatment, Rapid Immunotherapies
By Application
Hospitals, Clinics, Other
By Companies
Takeda, F. Hoffmann-La Roche, CSL Behring, Grifols, Alexion Pharmaceutical, Avadel Pharmaceuticals, Baxter International, Novartis, Bausch Health, Takeda Pharmaceutical Company
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
216
Number of Tables & Figures
152
Customization Available
Yes, the report can be customized as per your need.
Global Myasthenia Gravis Market Report Segments:
The global Myasthenia Gravis market is segmented on the basis of:
Types
Drug Treatment, Rapid Immunotherapies
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Takeda
- F. Hoffmann-La Roche
- CSL Behring
- Grifols
- Alexion Pharmaceutical
- Avadel Pharmaceuticals
- Baxter International
- Novartis
- Bausch Health
- Takeda Pharmaceutical Company
Highlights of The Myasthenia Gravis Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Drug Treatment
- Rapid Immunotherapies
- By Application:
- Hospitals
- Clinics
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Myasthenia Gravis Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Myasthenia gravis is a rare neuromuscular disorder that causes muscle weakness. The muscles become weak and can't contract properly, which can lead to difficulty breathing, swallowing, and speaking. Myasthenia gravis is usually caused by a virus or an autoimmune disease (a condition in which the body attacks its own cells). There's no known cure for myasthenia gravis, but treatments include medication and physical therapy.
Some of the key players operating in the myasthenia gravis market are Takeda, F. Hoffmann-La Roche, CSL Behring, Grifols, Alexion Pharmaceutical, Avadel Pharmaceuticals, Baxter International, Novartis, Bausch Health, Takeda Pharmaceutical Company.
The myasthenia gravis market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Myasthenia Gravis Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Myasthenia Gravis Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Myasthenia Gravis Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Myasthenia Gravis Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Myasthenia Gravis Market Size & Forecast, 2018-2028
4.5.1 Myasthenia Gravis Market Size and Y-o-Y Growth
4.5.2 Myasthenia Gravis Market Absolute $ Opportunity
Chapter 5 Global Myasthenia Gravis Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Myasthenia Gravis Market Size Forecast by Type
5.2.1 Drug Treatment
5.2.2 Rapid Immunotherapies
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Myasthenia Gravis Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Myasthenia Gravis Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Myasthenia Gravis Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Myasthenia Gravis Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Myasthenia Gravis Analysis and Forecast
9.1 Introduction
9.2 North America Myasthenia Gravis Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Myasthenia Gravis Market Size Forecast by Type
9.6.1 Drug Treatment
9.6.2 Rapid Immunotherapies
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Myasthenia Gravis Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.10.3 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Myasthenia Gravis Analysis and Forecast
10.1 Introduction
10.2 Europe Myasthenia Gravis Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Myasthenia Gravis Market Size Forecast by Type
10.6.1 Drug Treatment
10.6.2 Rapid Immunotherapies
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Myasthenia Gravis Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.10.3 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Myasthenia Gravis Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Myasthenia Gravis Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Myasthenia Gravis Market Size Forecast by Type
11.6.1 Drug Treatment
11.6.2 Rapid Immunotherapies
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Myasthenia Gravis Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.10.3 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Myasthenia Gravis Analysis and Forecast
12.1 Introduction
12.2 Latin America Myasthenia Gravis Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Myasthenia Gravis Market Size Forecast by Type
12.6.1 Drug Treatment
12.6.2 Rapid Immunotherapies
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Myasthenia Gravis Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.10.3 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Myasthenia Gravis Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Myasthenia Gravis Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Myasthenia Gravis Market Size Forecast by Type
13.6.1 Drug Treatment
13.6.2 Rapid Immunotherapies
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Myasthenia Gravis Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.10.3 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Myasthenia Gravis Market: Competitive Dashboard
14.2 Global Myasthenia Gravis Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Takeda
14.3.2 F. Hoffmann-La Roche
14.3.3 CSL Behring
14.3.4 Grifols
14.3.5 Alexion Pharmaceutical
14.3.6 Avadel Pharmaceuticals
14.3.7 Baxter International
14.3.8 Novartis
14.3.9 Bausch Health
14.3.10 Takeda Pharmaceutical Company
